CNSP News and Press, CNS Pharmaceuticals Inc. From 03/24/23

CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollme...

Around 700,000 Americans are estimated to be living with a primary brain tumor. The deadly condition has an incredibly high fatality rate , and it significantly disrupts the quality of life of brain cancer patients and their families. Although tumors can’t be completely cured, early det...

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken contro...

CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues PR Newswire HOUSTON , March 13, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the developm...

An estimated 8% of Americans aged 18 years and older suffer from chronic pain so severe that it limits their day-to-day activities. Epidemiological studies estimate that the overall prevalence of chronic pain among American adults is between 18% and 34.5% . For most of these people, opioids ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing ...

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland PR Newswire Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects...

Recent research has revealed that repeated head trauma can elevate the risk of developing brain cancer. The study found that repeated hits to the head can increase risk of a rare and aggressive brain tumor called glioma by more than four times. Brain injuries are the leading cause of... ...

Gainers: Cardio Diagnostics ( CDIO ) +159% . Bioventus ( BVS ) +68% . CNS Pharmaceuticals ( CNSP ) +24% . Bullfrog AI ( BFRG ) +20% . SI-BONE ( SIBN ) +19% . Losers: ContraFect ( CFRX ) -24% . AdaptHealth ( AHCO ) ...

Immunotherapy is one of the newest cancer treatment options that has made it possible for physicians to target and treat cancer more effectively. This treatment works by helping a patient’s immune system to kill cancer cells rather than using pharmaceuticals or radiation therapy to dire...